Scale Up

Innovations in downstream processing accelerate development, enhance efficiency, and promote sustainability.

Scale-up strategies for cell culture will require a deep understanding of overall bioprocess workflows.

Scaling cell therapy production workflows requires the establishment of closed, automated steps.

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

Improvement in viral vector yield has become integral to new cell and gene therapy product development.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Scaling up chromatography resins requires a thorough understanding of their intended use.

Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.

The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.

Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.

Mechanistic models provide process understanding for developing robust manufacturing processes and for scale up and tech transfer.

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

A unified scale-up approach, as presented here, can be applied to any unit operation.

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.

Scaling needs for potential COVID-19 vaccines depend not only on capacity, but also on supply chain challenges and technological hurdles.

Wacker will support production of CureVac’s COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021.

The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.

The company’s new closed cell therapy processing system enables scalable, cost-effective development and manufacturing of cell therapies.

Experience, communication, collaboration, transparency, planning, and prioritization contribute to success.

Used with perfusion, alternating tangential flow and tangential flow filtration are redefining upstream efficiency.

The company’s Custom Single Run product line now has available bioreactors with working volumes of up to 6000 L.

The new facility, located in Ness Ziona, Israel, will support clinical phage manufacturing and can be expanded in the future to support commercial-scale manufacturing.

The growing trend of partnerships between small biotech companies and CDMOs makes the need for conducting CMC due diligence increasingly important.

Increasingly complex monoclonal antibody molecules will require the right “tool box” for scaling up manufacturing.

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

A look at recent investments by contract manufacturers to increase single-use bioreactor capacity.